AU2003259249A1 - Pyridazinylpiperazine derivatives for treating pain - Google Patents

Pyridazinylpiperazine derivatives for treating pain

Info

Publication number
AU2003259249A1
AU2003259249A1 AU2003259249A AU2003259249A AU2003259249A1 AU 2003259249 A1 AU2003259249 A1 AU 2003259249A1 AU 2003259249 A AU2003259249 A AU 2003259249A AU 2003259249 A AU2003259249 A AU 2003259249A AU 2003259249 A1 AU2003259249 A1 AU 2003259249A1
Authority
AU
Australia
Prior art keywords
pyridazinylpiperazine
derivatives
treating pain
pain
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003259249A
Other languages
English (en)
Inventor
Donald J. Kyle
Qun Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of AU2003259249A1 publication Critical patent/AU2003259249A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
AU2003259249A 2002-07-26 2003-07-25 Pyridazinylpiperazine derivatives for treating pain Abandoned AU2003259249A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US39859402P 2002-07-26 2002-07-26
US60/398,594 2002-07-26
US41102002P 2002-09-17 2002-09-17
US60/411,020 2002-09-17
US41315502P 2002-09-25 2002-09-25
US60/413,155 2002-09-25
US41652502P 2002-10-08 2002-10-08
US60/416,525 2002-10-08
PCT/US2003/023377 WO2004011441A1 (en) 2002-07-26 2003-07-25 Pyridazinylpiperazine derivatives for treating pain

Publications (1)

Publication Number Publication Date
AU2003259249A1 true AU2003259249A1 (en) 2004-02-16

Family

ID=31192373

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003259249A Abandoned AU2003259249A1 (en) 2002-07-26 2003-07-25 Pyridazinylpiperazine derivatives for treating pain

Country Status (3)

Country Link
US (2) US7262194B2 (US07696207-20100413-C00025.png)
AU (1) AU2003259249A1 (US07696207-20100413-C00025.png)
WO (1) WO2004011441A1 (US07696207-20100413-C00025.png)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US7262194B2 (en) * 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20050009841A1 (en) * 2003-07-11 2005-01-13 Zheng Guo Zhu Novel amides useful for treating pain
US7129235B2 (en) 2003-07-11 2006-10-31 Abbott Laboratories Amides useful for treating pain
CN101935315A (zh) 2003-07-24 2011-01-05 欧洲凯尔蒂克公司 用于治疗或预防疼痛的杂芳基-四氢哌啶基化合物
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
SI1942106T1 (sl) * 2003-08-01 2012-01-31 Euro Celtique Sa Terapevtska sredstva, uporabna za zdravljenje bolečine
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US20080153845A1 (en) * 2006-10-27 2008-06-26 Redpoint Bio Corporation Trpv1 antagonists and uses thereof
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2833209C (en) * 2007-04-27 2016-06-28 Purdue Pharma L.P. Piperidine and piperazine compounds as trpv1 antagonists
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
TW200927731A (en) 2007-09-14 2009-07-01 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
CN101801951B (zh) 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
BRPI0920354A2 (pt) 2008-10-16 2017-06-27 Addex Pharmaceuticals Sa derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
GB0902173D0 (en) 2009-02-10 2009-03-25 Takeda Pharmaceutical Compounds and their use
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
RS53075B (en) 2009-05-12 2014-04-30 Janssen Pharmaceuticals Inc. 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8323702B2 (en) * 2010-01-28 2012-12-04 Okoro Chuks I Composition and method for treating ulcers
US8431575B2 (en) 2010-02-18 2013-04-30 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
US8921373B2 (en) 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JP6130827B2 (ja) 2011-05-17 2017-05-17 塩野義製薬株式会社 ヘテロ環化合物
CA2835885C (en) * 2011-05-17 2020-08-25 Niiki Pharma Aquisition Corp. 2 Medicaments and methods for treating cancer
UA113288C2 (xx) 2011-06-22 2017-01-10 Trpv1 антагоністи, що містять дигідроксизамісник, і їх застосування
WO2013146969A1 (ja) * 2012-03-29 2013-10-03 第一三共株式会社 新規二置換シクロヘキサン誘導体
JP2015516436A (ja) * 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬
US9296723B2 (en) 2012-05-11 2016-03-29 Abbvie Inc. NAMPT inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20160098506A (ko) 2013-12-20 2016-08-18 라보라토리오스 델 드라. 에스테브.에스.에이. 통증에 대한 다양한 활성을 갖는 피페라진 유도체
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN109561680B (zh) 2016-06-23 2021-07-13 圣朱德儿童研究医院 泛酸激酶的小分子调节剂
AU2018395222B2 (en) 2017-12-27 2023-06-08 Coa Therapeutics, Inc. Small molecule modulators of pantothenate kinases
AU2018397486A1 (en) 2017-12-27 2020-08-13 Coa Therapeutics, Inc. Methods of treating disorders associated with castor
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI56836C (fi) 1977-10-25 1980-04-10 Fermion Oy 4-substituerade piperazin-1-(n-aryl-n'-cyano)-karboximidamider som aer mellanprodukter vid framstaellningen av farmakologiskt vaerdefulla 6,7-dimetoxi- eller 6,7,8-trimetoxi-4-amino-2-(4-substituerade-piperazin-1-yl)-kinazoliner
US4450272A (en) * 1982-05-06 1984-05-22 American Cyanamid Company Antiatherosclerotic 1-piperazine-thicarboxamides
US4439606A (en) * 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5198459A (en) * 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5232934A (en) * 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
GB9306578D0 (en) * 1993-03-30 1993-05-26 Merck Sharp & Dohme Therapeutic agents
GB9308725D0 (en) * 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
US5461047A (en) * 1993-06-16 1995-10-24 G. D. Searle & Co. 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
FR2722788B1 (fr) * 1994-07-20 1996-10-04 Pf Medicament Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
US5762925A (en) * 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
PL183865B1 (pl) 1995-01-11 2002-07-31 Samjin Pharmaceutical Co Nowe pochodne piperazyny i środek farmaceutyczny
US5792769A (en) * 1995-09-29 1998-08-11 3-Dimensional Pharmaceuticals, Inc. Guanidino protease inhibitors
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
PL325341A1 (en) * 1996-06-29 1998-07-20 Samjin Pharmaceutical Co Derivatives od piperazine and method of obtaining them
JP2003524574A (ja) 1997-08-05 2003-08-19 ノボ ノルディスク アクティーゼルスカブ ２，５−及び３，５−二置換アニリン誘導体、その調製及び使用
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
EP1067123B1 (en) * 1998-03-31 2011-01-19 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
AU754529B2 (en) 1998-09-22 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
EP1140905B1 (en) 1998-12-23 2003-05-14 Eli Lilly And Company Heteroaromatic amides as inhibitor of factor xa
EP1146790A4 (en) 1999-01-25 2004-03-17 Smithkline Beecham Corp COMPOUNDS AND METHODS
GB9903476D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
AU763030B2 (en) 1999-03-03 2003-07-10 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
US6109269A (en) * 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion
JP2001328938A (ja) 2000-03-17 2001-11-27 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体を有効成分とする医薬
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
WO2001095856A2 (en) * 2000-06-15 2001-12-20 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
EP1313477A4 (en) 2000-07-15 2004-03-03 Smithkline Beecham Corp COMPILATIONS AND METHODS
WO2002006234A1 (fr) * 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Derives de sulfonate, procede de production et utilisation de ces derives
ATE374765T1 (de) * 2000-07-27 2007-10-15 Lilly Co Eli Substituierte heterocyclische amide
JP2004506714A (ja) * 2000-08-21 2004-03-04 パシフィック　コーポレーション 新規チオ尿素化合物及びこれを含有する薬学的組成物
ATE393141T1 (de) 2000-08-21 2008-05-15 Pacific Corp Neue thiourea-derivate und pharmazeutische zusammensetzungen die diese enthalten
TWI258469B (en) * 2001-03-19 2006-07-21 Dainippon Pharmaceutical Co Aryl-substituted alicyclic compounds and pharmaceutical composition containing the same
PE20030417A1 (es) 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
JP2003192673A (ja) 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
KR20040085151A (ko) 2002-01-17 2004-10-07 뉴로젠 코포레이션 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
JP4583760B2 (ja) * 2002-02-01 2010-11-17 ユーロ−セルティーク エス．エイ． 疼痛の治療に有用な治療薬
ES2316777T3 (es) 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EA200500114A1 (ru) * 2002-06-28 2005-06-30 Еуро-Селтик, С. А. Терапевтические агенты, используемые для лечения боли
US7262194B2 (en) * 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2004080411A2 (en) * 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto

Also Published As

Publication number Publication date
US20080200472A1 (en) 2008-08-21
US20040235853A1 (en) 2004-11-25
US7262194B2 (en) 2007-08-28
US7696207B2 (en) 2010-04-13
WO2004011441A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
AU2003259249A1 (en) Pyridazinylpiperazine derivatives for treating pain
IL209352A0 (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
AU2003280004A1 (en) Hair treatment method
AU2003249244A1 (en) Methods for the treatment of neoplasms
AU2003296475A1 (en) Phototherapy bandage
AU2003297762A1 (en) Methods for treating essential tremor
AU2003237159A1 (en) Treatment for phenylketonuria
AU2003275126A1 (en) Hemiasterlin derivatives for treating resistant tumors
AU2003283257A1 (en) Scalp treatment
AU2003256655A1 (en) Therapeutic compounds for treating dyslipidemic conditions
AUPS160602A0 (en) Therapeutic method
AU2002236781A1 (en) Treatment for snoring
AU2003233820A1 (en) Method for the treatment of starch
AU2003215150A1 (en) Therapeutic compounds
AU2003222449A1 (en) Medicine for treating cancer
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003261756A1 (en) Acrylamide derivatives
AU2002225327A1 (en) Apparatus for aesthetic treatment
AU2003275433A1 (en) Compositions and methods for treating pain
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2003299652A1 (en) Methods for treating diabetes
AU2003213109A1 (en) Method for treating cellulite
AU2003242991A1 (en) Apparatus for therapeutic treatments
AU2003248679A1 (en) Treating disease using radium-225
AU2003213349A1 (en) Therapeutic agent for pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase